论文部分内容阅读
目的:比较单独使用贝那普利与胰激肽原酶肠溶片联合贝那普利在治疗2型糖尿病肾病方面的临床疗效。方法:2型糖尿病肾病患者80例,根据患者情况分为2组,对照组单独使用贝那普利,治疗组采用胰激肽原酶肠溶片联合贝那普利治疗,共12周。比较治疗前后2组患者的血肌酐(CR)、24 h尿白蛋白排泄率(UAER)、血压(BP)等指标的变化。结果:2种治疗方法均可在一定程度上降低2型糖尿病肾病患者的UAER、CR、BP指标,但治疗组在降低UAER方面作用更加明显(P<0.05)。结论:对于2型糖尿病肾病患者,联合应用胰激肽原酶肠溶片和贝那普利,比单独使用贝那普利能够更加有效地减少2型糖尿病肾病患者的UAER,延缓糖尿病肾病病情。
OBJECTIVE: To compare the clinical efficacy of benazepril and pancreatic kallikrein combined with benazepril in the treatment of type 2 diabetic nephropathy. Methods: Eighty patients with type 2 diabetic nephropathy were divided into two groups according to the patients’ condition. The control group received benazepril alone. The treatment group was treated with pancreatic kallikrein combined with benazepril for 12 weeks. The changes of serum creatinine (CR), urinary albumin excretion rate (UAER), blood pressure (BP) and other indexes were compared between the two groups before and after treatment. Results: Both of the two treatment methods could reduce the UAER, CR and BP of type 2 diabetic nephropathy to a certain extent, but the treatment group was more effective in reducing UAER (P <0.05). CONCLUSIONS: In patients with type 2 diabetic nephropathy, the combination of pancreatic kallidinogenase enteric-coated tablets and benazepril may be more effective in reducing type 2 diabetes mellitus (UAER) and delaying the progression of diabetic nephropathy than benazepril alone.